CYBN (Cybin) רווח נקי למניה אחת בשנים עשר החודשים האחרונים

Cybin Inc. (CYBN) is a biopharmaceutical startup developing treatments for depression, where high future research costs are offset by patents and low-cost drug synthesis. Serving as the primary valuation tool, this price chart demonstrates an EPS of 35.20, underscoring its status as an ethical innovator in neuroscience. To complete its clinical trials, Cybin Inc. (CYBN) is betting on finding a strategic partner among industry behemoths.

The indicator is calculated as the percentage change in the rolling annual earnings per share compared to the same period last year. This metric measures the efficiency of net income generation, allowing for an assessment of business scaling rates. For Cybin Inc. (CYBN), high clinical trial costs suppress this growth, keeping the company in a pre-profit phase. By analyzing the year-over-year EPS (TTM) comparison, an investor can track the moment the company overcomes its operational plateau.